Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | HTT | P42858 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 1/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.82 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.82 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.78 |
| ▸ | CDK2 | P24941 | 2/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684654 | 0.90 | CACNA1B (1.00) | MAPTHTTKDM4ELMNAGAA | |
| Bromide SCHEMBL18040712 | 0.89 | CACNA1B (0.98) | MAPTHTTKDM4ELMNAGAA | |
| SCHEMBL1684622 | 0.88 | MAPT (0.98) | MAPTHTTKDM4ELMNAGAA | |
| SCHEMBL1684729 | 0.88 | MAPT (0.79) | MAPTHTTKDM4ELMNAGAA | |
| Bromide SCHEMBL18040722 | 0.87 | MAPT (0.77) | MAPTHTTKDM4ELMNAGAA | |
| Bromide SCHEMBL18040791 | 0.87 | MAPT (1.00) | MAPTHTTKDM4ELMNAGAA | |
| SCHEMBL12789774 | 0.87 | MAPT (0.76) | MAPTHTTKDM4ELMNAGAA | |
| SCHEMBL2355935 | 0.86 | MAPT (0.75) | MAPTHTTKDM4ELMNAGAA | |
| SCHEMBL1684910 | 0.86 | PRKD3 (0.78) | MAPTHTTKDM4ELMNAGAA | |
| SCHEMBL3644534 | 0.86 | MAPT (0.74) | MAPTHTTKDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | MAPT 4811/4885HTT 4767/4885KDM4E 1747/4885 |
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | MAPT 3849/4885HTT 3739/4885KDM4E 3440/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | MAPT 3849/4885HTT 3739/4885KDM4E 3440/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | MAPT 4240/4885HTT 4280/4885KDM4E 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.